[1]操利超,张核子,余晨笛,等.CLDN11在结肠癌中的预后价值及其作为潜在免疫治疗靶点的研究[J].医学信息,2022,35(14):10-15.[doi:10.3969/j.issn.1006-1959.2022.14.002]
　CAO Li-chao,ZHANG He-zi,YU Chen-di,et al.The Prognostic Value of CLDN11 in Colon Cancer and its Potential Immunotherapy Targets[J].Medical Information,2022,35(14):10-15.[doi:10.3969/j.issn.1006-1959.2022.14.002]
点击复制

CLDN11在结肠癌中的预后价值及其作为潜在免疫治疗靶点的研究()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
35卷
期数:
2022年14期
页码:
10-15
栏目:
生物信息学
出版日期:
2022-07-15

文章信息/Info

Title:
The Prognostic Value of CLDN11 in Colon Cancer and its Potential Immunotherapy Targets
文章编号:
1006-1959（2022）14-0010-06
作者:
操利超; 张核子; 余晨笛; 等
（深圳市核子基因科技有限公司，广东 深圳 518071）
Author(s):
CAO Li-chao; ZHANG He-zi; YU Chen-di; et al.
(Shenzhen Nucleus Gene Technology Co., Ltd., Shenzhen 518071,Guangdong,China)
关键词:
CLDN11; 结肠癌; 预后评估; 生物信息学; TCGA数据库
Keywords:
CLDN11; Colon cancer; Prognosis evaluation; Bioinformatics; TCGA database
分类号:
R714.24
DOI:
10.3969/j.issn.1006-1959.2022.14.002
文献标志码:
A
摘要:
目的 分析CLDN11在结肠癌等肿瘤样本中的表达情况，探讨其预后价值及其与常见的免疫治疗靶点基因的相关性。方法 利用TIMER2.0在线分析CLDN11在泛癌种中的基因表达情况，分析CLDN11基因的表达与免疫细胞侵润水平的相关性。利用GEPIA2在线分析CLDN11与结肠癌患者总生存时间（OS）和无病生存时间（DFS）的关联，评价其在泛癌种中的预后价值。从TCGA数据库中下载结肠癌相关的mRNA表达数据矩阵和临床信息，分析CLDN11基因的表达在TMN分期和微卫星状态的关系，以及与免疫治疗靶点的相关性。其中，相关性大小用相关性系数（cor）表示。结果 CLND11在多种肿瘤包括结肠癌中高表达，在胆管癌（CHOL）和甲状腺癌(THCA)中低表达，且CLDN11的低表达与多种肿瘤患者的良好预后显著相关（P＜0.05）；Kruskal-wallis检验结果表明，CLDN11的高表达与较高的T分期（P=0.019）、M分期（P=0.0076）、N分期（P=0.0043）、病理分期（P=0.013）和较稳定的微卫星状态（P=5.4e-5）相关。CLDN11的表达与免疫治疗靶点基因CD274、CTLA4、HAVCR2、LAG3、PDCD1、TIGIT的表达显著正相关（cor＞0.25，P＜0.05）。结论 CLDN11可作为多种肿瘤的预后标志物，且可作为结肠癌肿瘤分期的预测因子和潜在的免疫治疗靶点。
Abstract:
Objective To analyze the expression of CLDN11 in colon cancer and other tumor samples, and to explore its prognostic value and its correlation with common immunotherapy target genes.Methods TIMER2.0 was used to analyze the gene expression of CLDN11 in pan-cancer species online, and the correlation between CLDN11 gene expression and immune cell invasion was analyzed. GEPIA2 was used to online analyze the correlation between CLDN11 and total survival time (OS) and disease-free survival time (DFS) of colon cancer patients, and to evaluate its prognostic value in pan-cancer species. Download the mRNA expression data matrix and clinical information related to colon cancer from TCGA database, analyze the relationship between CLDN11 gene expression in TMN stage and microsatellite status, and the correlation with immunotherapy targets. where the correlation was expressed by the correlation coefficient (cor).Results CLND11 was highly expressed in various tumors, including colon cancer, and lowly expressed in cholangiocarcinoma ( CHOL ) and thyroid cancer (THCA). The low expression of CLDN11 was significantly correlated with the good prognosis of patients with various tumors (P<0.05). The Kruskal-wallis test results showed that the high expression of CLDN11 was related to higher T staging (P=0.019), M staging (P=0.0076), N staging (P=0.0043), pathological staging (P=0.013) and stable microsatellite status (P=5.4e-5). The expression of CLDN11 was significantly positively correlated with the expression of CD274, CTLA4, HAVCR2, LAG3, PDCD1 and TIGIT (cor>0.25, P<0.05).Conclusion CLDN11 can be used as a prognostic marker for a variety of tumors, and can be used as a predictor of tumor staging of colon cancer and a potential target for immunotherapy.

参考文献/References:

[1]Siegel RL,Miller KD,Fuchs HE,et al.Cancer statistics,2022[J].CA Cancer J Clin,2022,72(1):7-33.[2]Lei X,Lei Y,Li JK,et al.Immune cells within the tumor microenvironment:Biological functions and roles in cancer immunotherapy[J].Cancer Lett,2020,470:126-133.[3]Hinshaw DC,Shevde LA.The Tumor Microenvironment Innately Modulates Cancer Progression[J].Cancer Res,2019,79(18):4557-4566.[4]Xiao Y,Yu D.Tumor microenvironment as a therapeutic target in cancer[J].Pharmacol Ther,2021,221:107753.[5]Cao L,Li T,Ba Y,et al.Exploring Immune-Related Prognostic Signatures in the Tumor Microenvironment of Colon Cancer[J].Front Genet,2022,13:801484.[6]Cao L,Chen E,Zhang H,et al.Construction of a novel methylation-related prognostic model for colorectal cancer based on microsatellite status[J].J Cell Biochem,2021,122(12):1781-1790.[7]Herrera M,Berral-Gonzalez A,Lopez-Cade I,et al.Cancer-associated fibroblast-derived gene signatures determine prognosis in colon cancer patients[J].Mol Cancer,2021,20(1):73.[8]Li X,Wen D,Li X,et al.Identification of an Immune Signature Predicting Prognosis Risk and Lymphocyte Infiltration in Colon Cancer[J].Front Immunol,2020,11:1678.[9]Lu Y,Jing J,Sun L,et al.Expression of claudin-11,-23 in different gastric tissues and its relationship with the risk and prognosis of gastric cancer[J].PLoS One,2017,12(3):e0174476.[10]Yang G,Jian L,Chen Q.Comprehensive analysis of expression and prognostic value of the claudin family in human breast cancer[J].Aging(Albany NY),2021,13(6):8777-8796.[11]Rahman A,Kobayashi M,Sugimoto K,et al.Reduced Claudin-12 Expression Predicts Poor Prognosis in Cervical Cancer[J].Int J Mol Sci,2021,22(7):3774.[12]Zhang C,Guo C,Li Y,et al.Identification of Claudin-6 as a Molecular Biomarker in Pan-Cancer Through Multiple Omics Integrative Analysis[J].Front Cell Dev Biol,2021,9:726656.[13]Li T,Fu J,Zeng Z,et al.TIMER2.0 for analysis of tumor-infiltrating immune cells[J].Nucleic Acids Res,2020,48(W1):W509-W514.[14]Tang Z,Kang B,Li C,et al.GEPIA2:an enhanced web server for large-scale expression profiling and interactive analysis[J].Nucleic Acids Res,2019,47(W1):W556-W560.[15]Li HP,Peng CC,Wu CC,et al.Inactivation of the tight junction gene CLDN11 by aberrant hypermethylation modulates tubulins polymerization and promotes cell migration in nasopharyngeal carcinoma[J].J Exp Clin Cancer Res,2018,37(1):102.[16]Li J,Zhou C,Ni S,et al.Methylated claudin-11 associated with metastasis and poor survival of colorectal cancer[J].Ncotarget,2017,8(56):96249-96262.[17]Shen Z,Cao B,Lin L,et al.The Clinical Signification of Claudin-11 Promoter Hypermethylation for Laryngeal Squamous Cell Carcinoma[J].Med Sci Monit,2017,23:3635-3640.[18]Cherradi S,Martineau P,Gongora C,et al.Claudin gene expression profiles and clinical value in colorectal tumors classified according to their molecular subtype[J].Cancer Manag Res,2019,11:1337-1348.[19]Yang G,Jian L,Chen Q.Comprehensive analysis of expression and prognostic value of the claudin family in human breast cancer[J].Aging,2021,13(6):8777-8796.[20]Wang Y,Shi H,Zhang Y,et al.Identification of Differentially Expressed Hub Genes Associated With Immune Cell Recruitment in Claudin-Low Breast Cancer[J].Front Oncol,2022,12:848206.[21]Borst J,Ahrends T,Babala N,et al.CD4(+) T cell help in cancer immunology and immunotherapy[J].Nat Rev Immunol,2018,18(10):635-647.[22]Anderson NR,Minutolo NG,Gill S,et al.Macrophage-Based Approaches for Cancer Immunotherapy[J].Cancer Res,2021,81(5):1201-1208.[23]Giese MA,Hind LE,Huttenloche RA.Neutrophil plasticity in the tumor microenvironment[J].Blood,2019,133(20):2159-2167.[24]Lee YS,Radford KJ.The role of dendritic cells in cancer[J].Int Rev Cell Mol Biol,2019,348:123-178.[25]Lin A,Zhang J,Luo P.Crosstalk Between the MSI Status and Tumor Microenvironment in Colorectal Cancer[J].Front Immunol,2020,11:2039.[26]Bao X,Zhang H,Wu W,et al.Analysis of the molecular nature associated with microsatellite status in colon cancer identifies clinical implications for immunotherapy[J].J Immunother Cancer,2020,8:e001437.[27]Zhang X,Wu T,Cai X,et al.Neoadjuvant Immunotherapy for MSI-H/dMMR Locally Advanced Colorectal Cancer:New Strategies and Unveiled Opportunities[J].Front Immunol,2022,13:795972.

相似文献/References:

[1]苏周荣,杜东霖,魏正强.左半结肠癌伴梗阻一期切除吻合策略研究[J].医学信息,2018,31(10):51.[doi:10.3969/j.issn.1006-1959.2018.10.016]
　SU Zhou-rong,DU Dong-lin,WEI Zheng-qiang.Strategy of One-stage Resection and Anastomosis for Left Colon Cancer with Obstruction[J].Medical Information,2018,31(14):51.[doi:10.3969/j.issn.1006-1959.2018.10.016]
[2]崔忠泽,何 双,路丽祯,等.基于生物信息学分析筛选结肠癌关键基因[J].医学信息,2022,35(10):1.[doi:10.3969/j.issn.1006-1959.2022.10.001]
　CUI Zhong-ze,HE Shuang,LU Li-zhen,et al.Screening Key Genes of Colon Cancer Based on Bioinformatics Analysis[J].Medical Information,2022,35(14):1.[doi:10.3969/j.issn.1006-1959.2022.10.001]
[3]石 磊,孙新增,李宝山,等.Ⅱ、Ⅲ期结肠癌患者辅助化疗XELOX方案、FOLFOX方案的临床疗效、不良反应及生活质量对比[J].医学信息,2018,31(13):68.[doi:10.3969/j.issn.1006-1959.2018.13.020]
　SHI Lei,SUN Xin-zeng,LI Bao-shan,et al.Clinical Efficacy,Adverse Reactions and Quality of Life of Adjuvant Chemotherapy XELOX and FOLFOX in Patients with Stage II and III Colon Cancer[J].Medical Information,2018,31(14):68.[doi:10.3969/j.issn.1006-1959.2018.13.020]
[4]王 超,范小华,张 力,等.下腔静脉畸形伴腹腔多脏器异位合并结肠癌1例[J].医学信息,2018,31(18):188.[doi:10.3969/j.issn.1006-1959.2018.18.062]
　WANG Chao,FAN Xiao-hua,ZHANG Li,et al.a Case of Inferior Vena Cava Malformation Associated with Multiple Abdominal Organ Ectopic Colon Cancer[J].Medical Information,2018,31(14):188.[doi:10.3969/j.issn.1006-1959.2018.18.062]
[5]黄富全.结合靶向药物综合治疗结肠癌肝及肝外转移术后7年1例报告[J].医学信息,2019,32(01):186.[doi:10.3969/j.issn.1006-1959.2019.01.061]
[6]葛菁茹,朱静雅,苏日新,等.以肺转移为首发表现的结肠癌预后分析[J].医学信息,2021,34(04):96.[doi:10.3969/j.issn.1006-1959.2021.04.025]
　GE Jing-ru,ZHU Jing-ya,SU Ri-xin,et al.Prognostic Analysis of Colon Cancer with Lung Metastasis as the First Manifestation[J].Medical Information,2021,34(14):96.[doi:10.3969/j.issn.1006-1959.2021.04.025]
[7]韩 猛,薛三宝,倪 丰.CT与MRI术前诊断结肠癌及评价术后复发的价值[J].医学信息,2021,34(21):175.[doi:10.3969/j.issn.1006-1959.2021.21.050]
　HAN Meng,XUE San-bao,NI Feng.Value of CT and MRI in Preoperative Diagnosis and Postoperative Recurrence of Colon Cancer[J].Medical Information,2021,34(14):175.[doi:10.3969/j.issn.1006-1959.2021.21.050]
[8]操利超,巴 颖,卢晓萍,等.基于TCGA和GEO数据库构建结肠癌预后模型[J].医学信息,2021,34(24):27.[doi:10.3969/j.issn.1006-1959.2021.24.006]
　CAO Li-chao,BA Ying,LU Xiao-ping,et al.Prognostic Model of Colon Cancer Based on TCGA and GEO Database[J].Medical Information,2021,34(14):27.[doi:10.3969/j.issn.1006-1959.2021.24.006]
[9]张秀娟,黄丽娟.mTOR、PTEN、Ki-67蛋白表达水平变化与结肠癌病理学特征的相关性分析[J].医学信息,2022,35(19):54.[doi:10.3969/j.issn.1006-1959.2022.19.014]
　ZHANG Xiu-juan,HUANG Li-juan.Correlation of mTOR, PTEN and Ki-67 Protein Expression with Pathological Features of Colon Cancer[J].Medical Information,2022,35(14):54.[doi:10.3969/j.issn.1006-1959.2022.19.014]
[10]李 洋.北京市海淀区居民结肠癌防治知识知晓情况分析[J].医学信息,2021,34(08):141.[doi:10.3969/j.issn.1006-1959.2021.08.037]
　LI Yang.Analysis of Knowledge About Colon Cancer Prevention and Treatment Among Residents in Haidian District,Beijing[J].Medical Information,2021,34(14):141.[doi:10.3969/j.issn.1006-1959.2021.08.037]

更新日期/Last Update: 1900-01-01